Active Ingredient History
Relebactum sodium (MK-7655) is a piperidine analog 3 that inhibits class A and C β-lactamases (in vitro). It is being investigated for use in treatment of infectious diseases, such as treatment of gram-negative bacterial infections. Its potential as an alternative to existing medicines in the treatment of drug-resistant bacterial infections is being studied. Clinical trials have been conducted and are still ongoing to evaluate the efficacy and safety of relebactum sodium in treatment of intra-abdominal infections, urinary tract infections (such as pyelonephritis), hospital-acquired and ventilator-associated bacterial pneumonias, and gram-negative bacterial infections. NCATS
Combination drugs
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Pneumonia, Bacterial (approved 2020)
Urinary Tract Infections (approved 2019)
Bacterial Infections (Phase 4)
Carbapenems (Phase 4)
Communicable Diseases (Phase 1)
Critical Illness (Phase 4)
Cystic Fibrosis (Phase 4)
Gram-Negative Bacterial Infections (Phase 4)
Healthcare-Associated Pneumonia (Phase 3)
Intraabdominal Infections (Phase 2)
Lymphoma (Phase 2)
Neoplasms (Phase 2)
Obesity (Phase 4)
Pneumonia, Bacterial (Phase 4)
Pneumonia, Ventilator-Associated (Phase 3)
Pyelonephritis (Phase 2)
Sepsis (Phase 1)
Urinary Tract Infections (Phase 3)
Ventilators, Mechanical (Phase 3)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue